MX2015007665A - Pharmaceutical composition for veterinary use in a progesterone suspension in a polymric system, which has gelling properties in situ. - Google Patents

Pharmaceutical composition for veterinary use in a progesterone suspension in a polymric system, which has gelling properties in situ.

Info

Publication number
MX2015007665A
MX2015007665A MX2015007665A MX2015007665A MX2015007665A MX 2015007665 A MX2015007665 A MX 2015007665A MX 2015007665 A MX2015007665 A MX 2015007665A MX 2015007665 A MX2015007665 A MX 2015007665A MX 2015007665 A MX2015007665 A MX 2015007665A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
situ
ranging
veterinary use
gelling properties
Prior art date
Application number
MX2015007665A
Other languages
Spanish (es)
Inventor
Josefa Bernad Bernad María
Karen Lugo Espinosa Ana
Urbiola Verdejo Gonzalo
Original Assignee
Univ Nac Autónoma De México
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nac Autónoma De México filed Critical Univ Nac Autónoma De México
Priority to MX2015007665A priority Critical patent/MX2015007665A/en
Priority to PCT/MX2016/000061 priority patent/WO2016204598A1/en
Publication of MX2015007665A publication Critical patent/MX2015007665A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention is related to a pharmaceutical composition of veterinary use based on a progesterone suspension in a polymeric system, which comprises: an effective amount of progesterone ranging from 2 % to 20% w/v; an effective amount of a copolymer in suspension ranging from 3 % to 60 % w/v: an effective amount of polyethylenglycol ranging from 10 % to 30% w/v, where said polyethylenglycol has molecular weights ranging from 400 to 20000 Da; a suitable amount for 50 ml of a solvent that is selected from a mixture of water/ethanol, a mixture of N-methyl pyrrolidine/water or a mixture of N-methyl pyrrolidine/water/ethanol; where said pharmaceutical composition is administered by modified release and parenteral via, also having gelling properties in situ. In addition, said pharmaceutical composition is useful for controlling fertility in different animal species.
MX2015007665A 2015-06-16 2015-06-16 Pharmaceutical composition for veterinary use in a progesterone suspension in a polymric system, which has gelling properties in situ. MX2015007665A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MX2015007665A MX2015007665A (en) 2015-06-16 2015-06-16 Pharmaceutical composition for veterinary use in a progesterone suspension in a polymric system, which has gelling properties in situ.
PCT/MX2016/000061 WO2016204598A1 (en) 2015-06-16 2016-06-16 Pharmaceutical composition for veterinary use, comprising a suspension of progesterone in a polymer system and having in situ gelling properties

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2015007665A MX2015007665A (en) 2015-06-16 2015-06-16 Pharmaceutical composition for veterinary use in a progesterone suspension in a polymric system, which has gelling properties in situ.

Publications (1)

Publication Number Publication Date
MX2015007665A true MX2015007665A (en) 2016-12-15

Family

ID=57546082

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015007665A MX2015007665A (en) 2015-06-16 2015-06-16 Pharmaceutical composition for veterinary use in a progesterone suspension in a polymric system, which has gelling properties in situ.

Country Status (2)

Country Link
MX (1) MX2015007665A (en)
WO (1) WO2016204598A1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022554A (en) * 1997-12-15 2000-02-08 American Home Products Corporation Polymeric microporous film coated subcutaneous implant

Also Published As

Publication number Publication date
WO2016204598A1 (en) 2016-12-22

Similar Documents

Publication Publication Date Title
MX2020005873A (en) 6-azaindole compounds.
MX2023008041A (en) Nucleic acid-polypeptide compositions and uses thereof.
PH12018501226A1 (en) Methods for treating huntingtons disease
MX2021005348A (en) Pyridazinone compounds and uses thereof.
WO2019126253A8 (en) Aryl and heteroaryl substituted indole compounds
MX2021005350A (en) Pyridazinone compounds and uses thereof.
MX2021005214A (en) TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS.
MX2019014514A (en) Compounds for treating huntington's disease.
BR112019006642A2 (en) highly potent multimeric e-selectin antagonists
MX2015011132A (en) Polycyclic estrogen receptor modulators and uses thereof.
MX2023006541A (en) Fixed dose formulations.
BR112017013661A8 (en) Anthracycline-derived conjugate (pnu), drug-binding protein conjugate (bpdc), method for producing a drug-binding protein conjugate (bpdc), use of a binding protein-drug conjugate (bpdc) and pharmaceutical composition
MX2019013690A (en) Cyclodextrin protein drug conjugates.
MX2020001832A (en) Pyruvate kinase activators for use in treating blood disorders.
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
MX2013002975A (en) Estrogen receptor modulators and uses thereof.
MY187047A (en) Selective pyy compounds and uses thereof
MX2023000677A (en) Estrogen receptor-modulating compounds.
MX2017015879A (en) Hydroxypropyl beta-cyclodextrin compositions and methods.
BR112017008282B8 (en) Cross-linked metallocene-catalyzed polyethylene copolymer and pipe
MY197064A (en) Oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
BR112018071364A2 (en) hydrogenated block copolymer, polypropylene resin composition, and molded body
PH12019550275A1 (en) Methods and compositions for substance use disorder vaccine formulations and uses thereof
BR112017002569A2 (en) adhesive compositions comprising low molecular weight functionalized olefin-based polymers
MX2020003185A (en) Novel heterocyclic compounds as modulators of mglur7.

Legal Events

Date Code Title Description
FG Grant or registration